Cargando…
Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
BACKGROUND: Many patients with classical Hodgkin lymphoma show increased programmed death-1 ligand expression in Reed–Sternberg cells. We report the final results of a phase II study of nivolumab, an anti-programmed death-1 monoclonal antibody, in Japanese patients with relapsed or refractory classi...
Autores principales: | Maruyama, Dai, Terui, Yasuhito, Yamamoto, Kazuhito, Fukuhara, Noriko, Choi, Ilseung, Kuroda, Junya, Ando, Kiyoshi, Hattori, Akira, Tobinai, Kensei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579338/ https://www.ncbi.nlm.nih.gov/pubmed/32776097 http://dx.doi.org/10.1093/jjco/hyaa117 |
Ejemplares similares
-
Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017) -
Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma
por: Kawai, Hidetsugu, et al.
Publicado: (2021) -
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
por: Munakata, Wataru, et al.
Publicado: (2022) -
Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study
por: Kinoshita, Tomohiro, et al.
Publicado: (2020) -
Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)